CORD-19:dc97e1de3b69da13f534f15afdcedbf48064c69d / 762735-762894 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"T45195","span":{"begin":0,"end":159},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Administration of piroxicam (Feldene, 0.3 mg/kg PO q24-48h) with or without chemotherapy may shrink the tumor mass and delay the progression of clinical signs."}

{"project":"Epistemic_Statements","denotations":[{"id":"T2474","span":{"begin":0,"end":159},"obj":"Epistemic_statement"}],"text":"Administration of piroxicam (Feldene, 0.3 mg/kg PO q24-48h) with or without chemotherapy may shrink the tumor mass and delay the progression of clinical signs."}

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T148","span":{"begin":0,"end":159},"obj":"Sentence"}],"text":"Administration of piroxicam (Feldene, 0.3 mg/kg PO q24-48h) with or without chemotherapy may shrink the tumor mass and delay the progression of clinical signs."}

{"project":"CORD-19-PD-HP","denotations":[{"id":"T3973","span":{"begin":104,"end":109},"obj":"Phenotype"}],"attributes":[{"id":"A3973","pred":"hp_id","subj":"T3973","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"Administration of piroxicam (Feldene, 0.3 mg/kg PO q24-48h) with or without chemotherapy may shrink the tumor mass and delay the progression of clinical signs."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T3532","span":{"begin":104,"end":109},"obj":"Disease"},{"id":"T77557","span":{"begin":104,"end":109},"obj":"Disease"}],"attributes":[{"id":"A3532","pred":"mondo_id","subj":"T3532","obj":"http://purl.obolibrary.org/obo/MONDO_0005070"},{"id":"A27414","pred":"mondo_id","subj":"T77557","obj":"http://purl.obolibrary.org/obo/MONDO_0005070"}],"text":"Administration of piroxicam (Feldene, 0.3 mg/kg PO q24-48h) with or without chemotherapy may shrink the tumor mass and delay the progression of clinical signs."}